Bajaj Healthcare share price today

Bajaj Healthcare Ltd's share price was ₹308.60 at the close on 4 November 2026. It has been falling for 66 weeks. That is 10.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹284 and ₹448, and at that close it sat 15% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Bajaj Healthcare Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

Over the last 11 years the share price moved +614% while the NIFTY 500 moved +231%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: highest quarterly revenue in 16 quarters.

1. Highest quarterly revenue in 16 quarters

   Revenue of ₹176 crore in the September 2026 quarter is the highest of the last 16 quarters.

   Why: Revenue hit its highest level in 16 quarters because the company sold more medicine ingredients abroad and more finished medicine products. That more than covered weaker sales of ingredients in India.

   Next results: check whether Cenobamate repeat orders turn into steady demand, because management said early stocking was more than regular demand.

   From the earnings call on 19 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Bajaj Healthcare reported revenue of ₹176 crore, up 18.9% from ₹148 crore a year earlier, and a profit of ₹14.0 crore, up 27.3% from ₹11.0 crore.

Bajaj Healthcare results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Bajaj Healthcare's management discussed these results on a call held on 19 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Bajaj Healthcare closed at ₹308.60 on 4 November 2026, down 30.3% from ₹442.50 a year earlier (7 November 2025) and down 19.3% over five years. Its highest weekly close since May 2016 was ₹708.85 on 21 March 2025.

Bajaj Healthcare share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

537 weekly closes from 13 May 2016 to 4 November 2026.

4 Nov 2026: Bajaj Healthcare closed at ₹308.60, up 0.8% on the week and down 4.6% on the month. 19 Oct 2026: Bajaj Healthcare held its results call for July to September 2026. Management guided: FY29 revenue ₹900-1,000 crore and operating margin 18%-21%.

Earlier

• Results for July to September 2026: Revenue up 18.9% and profit up 27.3% on a year earlier.
• 11 Sep 2026: ex-date for a dividend of ₹1.50 a share, record date 14 Sep 2026.

Bajaj Healthcare paid ₹1.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.49% at the ₹308.60 close on 4 November 2026. The last was a dividend of ₹1.50 a share, ex-date 11 September 2026.

Bajaj Healthcare dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Bajaj Healthcare Ltd paid out 32% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 19 October 2026, Bajaj Healthcare's management guided: FY29 revenue ₹900-1,000 crore and operating margin 18%-21%.

“Once we start commercial production, which, as I mentioned, will be in Q2 FY28, it will take another 6-10 months to receive approvals from customers.”Anil Jain, on the call for July to September 2026

What management guided

• FY27 revenue and profit growth of 10%-15%, with operating margin of 18%-20%, reaffirmed as on track.
• FY27 capital spending ₹65-80 crore, annual capital spending ₹50-60 crore thereafter, and FY27 operating cash flow above ₹30 crore.
• Peptide plant capacity 250 kg/year; completion by March 2027, commercial production in July to September 2027, customer approvals another 6-10 months; first-year revenue ₹70-100 crore and cumulative revenue around ₹300 crore the following year.
• Genrx/Nashik facility expected operational in April to June 2027; revenue potential ₹200-250 crore over the next 2-3 years.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 19 October 2026.

When Bajaj Healthcare reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Peptide construction and customer-approval progress - check movement toward commercial production and customer readiness.

Bajaj Healthcare is on one of our India lists: Pharma stocks.

Bajaj Healthcare Ltd earned ₹14.0 Cr of net profit in the Sep 2026 quarter, +27.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹16.0 Cr. Over 10 years profit has grown 7.2% a year on average. That is 8.0% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹11.0 Cr. 3 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹16.0 Cr (−60.0% on the year before).

Why profit moved: revenue changed +18.9% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed −58.0% and revenue +15.1%. Profit is growing slower than sales: rising costs are taking part of the growth.

Bajaj Healthcare Ltd reported ₹176 Cr of revenue in the Sep 2026 quarter, +18.9% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 10.6% a year on average. The last full year, FY26, came in at ₹611 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹656 Cr.

FY26 revenue was ₹611 Cr, +12.5% on the year before.

Recent pace: the last four quarters grew +15.1% on average, against 10.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +14.3%, against +13.6% a year over the last 8 quarters (stabilising).

Bajaj Healthcare Ltd's operating margin was 18.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 13 years it has been between 9.0% and 21.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed −0.5 percentage points on the year while gross margin changed −2.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 59% of Bajaj Healthcare Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹58.0 Cr of operating cash against ₹16.0 Cr of profit. After ₹43.0 Cr of spending on assets, ₹15.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 59% of profit came in as cash: the cash cycle got 174 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: it has been selling more assets than it buys. The next section shows those figures.

Bajaj Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 256 days in FY26, up from 82 days in FY21. Over the last 3 years it sold more assets than it bought, by ₹48.0 Cr. Customers take 140 days to pay, and stock sits for 249 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹611 Cr, each day of that cycle ties up about ₹1.7 Cr, so roughly ₹429 Cr is tied up in the business at any time.

FY26: customers took 140 days to pay and stock sat for 249 days, about 8.2 months of sales sitting as stock, for a full cycle of 256 days, longer than FY21's 82.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 249 days. Customers pay about 140 days after that. Suppliers are paid at 133 days. Together that makes the 256-day cycle.

Over the last 3 years, money from selling assets was ₹48.0 Cr more than it spent on new ones. Work still in progress is ₹8.0 Cr (FY26).

In short: assets are being sold, not built, so this cash is not going into new capacity.

Bajaj Healthcare Ltd's P/E is 17.9×, in the middle of its own history: higher than 39% of past readings. Its usual P/E (the middle reading) is 20.1×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.